Immunic, Inc. ( Immunic," we, us, our or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gr felfing near Munich, Germany.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$112M
▲ +3.3% YoY
Op. Margin
–
ROIC
-127.72%
▼ -503.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$88M
▼ -1.1% YoY
Op. Cash Flow (TTM)
-$88M
▼ -1.2% YoY
Net Debt
-$155M
Net Cash Position
Cash & Equiv.
$155M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with IMUX
Held by ETFs
IMUX is in 2 US ETFs. The largest of them, with IMUX's weight in each:
Immunic (IMUX) in two numbers
Questions about Immunic
Does Immunic (IMUX) pay a dividend?
No. Immunic (IMUX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IMUX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMUX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.